Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REACH-2
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 23 Jan 2023 Last checked against ClinicalTrials.gov record.
- 20 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 09 Dec 2022 Results from an expansion cohort of this study published in the Oncologist